Volumetric 3D bioprinter manufacturer and EPFL spin-out Readily3D has taken the first step towards developing a 3D printed living model of the human pancreas for testing diabetes medicines.
Readily3D’s novel technology is being deployed within the EU-funded Enlight project and is reportedly capable of 3D printing a biological tissue containing human stem cells in just 30 seconds.
As the project’s official bioprinter manufacturer, the company has adapted its proprietary contactless tomographic illumination technology to suit the specific needs of pancreatic tissue structures.
Leave a reply